Latest News and Press Releases
Want to stay updated on the latest news?
-
IRVINE, Calif., Oct. 31, 2007 (PRIME NEWSWIRE) -- Lantronix, Inc. (Nasdaq:LTRX), a leader in device networking and data center management technologies, will report financial results for the first...
-
VANCOUVER, British Columbia, Oct. 31, 2007 (PRIME NEWSWIRE) -- Zecotek Medical Systems Inc. (TSX-V:ZMS) (Frankfurt:W1I) today announced that the Malaysian Institute for Micro-electronics Systems...
-
Key Figures (in EUR thousand) * Revenue: 466 in Q3 2007, down by 61% (Q3 2006: 1,203) * EBIT: -3,229 in Q3 2007, improved by 15% (Q3 2006: -3,790) * Net loss: -3,139 in Q3 2007, improved...
-
Enrolment to the phase I/II-clinical trial testing ChronVac-C® for the treatment of chronic hepatitis C virus infection has started As of yesterday, Monday the 29th of October, the enrolment of...
-
Patient-rekrytering till fas I/II-studien av ChronVac-C® för behandling av kronisk hepatit C virusinfektion har påbörjats Igår startade patient-rekryteringen den kliniska studien av det...
-
MUKILTEO, Wash., Oct. 26, 2007 (PRIME NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX) announced today that it has been invited to present at Friedland Investment Events' Life Sciences Conference in...
-
Bokslutskommuniké för Diamyd Medical AB (publ) (www.omxgroup.com ticker: DIAM B; www.otcqx.com ticker: DMYDY) 1 september 2006 - 31 augusti 2007 • Typ 1-diabetesprojekt fortskrider mot fas III...
-
Interim Report January - September 2007 Tripep AB (publ.) • Research and development costs amounted to SEK 13.3 million • The loss after tax was SEK -21.7 million • Earnings per share were SEK...
-
Delårsrapport januari - september 2007 Tripep AB (publ.) • Forsknings- och utvecklingskostnader 13,3 MSEK • Resultat efter skatt -21,7 MSEK • Resultat per aktie -0,45 SEK • Bolaget hade ingen...
-
MARTINSRIED, Germany, Oct. 25, 2007 (PRIME NEWSWIRE) -- MorphoSys AG (Frankfurt:MOR) (Prime Standard Segment, TecDAX) today reported financial results according to IFRS for the third quarter and the...